The National Institute of Allergy and Infectious Diseases (NIAID) intends to solicit proposals for contracts to advance the development of candidate medical countermeasures (MCMs) associated with exposure of the lungs to radiation from a radiological or nuclear incident.
NIAID anticipates that research and development studies supported by this Broad Agency Announcement will advance candidate MCMs toward eventual FDA approval or licensure to mitigate or treat radiation-induced pulmonary injury and thereby improve survival.
For this Broad Agency Announcement, it is anticipated that candidate MCMs will enter the evaluation and development pathway at various stages, from early research to post marketing (for drugs or biologics that are already licensed or approved for other indications).
It is anticipated that 2-4 cost reimbursement; completion type contracts will be awarded for a 3-year period of performance beginning on or about June 1, 2015.
Further details are available under Solicitation Number: BAA-NIAID-DAIT-NIHAI2014001.
